Popanda Odilia, Schattenberg Torsten, Phong Chi Tai, Butkiewicz Dorota, Risch Angela, Edler Lutz, Kayser Klaus, Dienemann Hendrik, Schulz Volker, Drings Peter, Bartsch Helmut, Schmezer Peter
Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Carcinogenesis. 2004 Dec;25(12):2433-41. doi: 10.1093/carcin/bgh264. Epub 2004 Aug 27.
Several polymorphisms in DNA repair genes have been reported to be associated with lung cancer risk including XPA (-4G/A), XPD (Lys751Gln and Asp312Asn), XRCC1 (Arg399Gln), APE1 (Asp148Glu) and XRCC3 (Thr241Met). As there is little information on the combined effects of these variants, polymorphisms were analyzed in a case-control study including 463 lung cancer cases [among them 204 adenocarcinoma and 212 squamous cell carcinoma (SCC)] and 460 tumor-free hospital controls. Odds ratios (OR) adjusted for age, gender, smoking and occupational exposure were calculated for the variants alone and combinations thereof. For homozygous individuals carrying the Glu variant of APE1, a protective effect was found (OR = 0.77, CI = 0.51-1.16). Individuals homozygous for the variants XPA (-4A) (OR = 1.53, CI = 0.94-2.5), XPD 751Gln (OR = 1.39, CI = 0.90-2.14) or XRCC3 241Met (OR = 1.29, CI = 0.85-1.98) showed a slightly higher risk for lung cancer overall. In the subgroup of adenocarcinoma cases, adjusted ORs were increased for individuals homozygous for XPA (-4A) (OR = 1.62, CI = 0.91-2.88) and XRCC3 241Met (OR = 1.65; CI = 0.99-2.75). When analyzing the combined effects of variant alleles, 54 patients and controls were identified that were homozygous for two or three of the potential risk alleles [i.e. the variants in nucleotide excision repair, XPA (-4A) and XPD 751Gln, and in homologous recombination, XRCC3-241Met]. ORs were significantly increased when all patients (OR = 2.37; CI = 1.26-4.48), patients with SCC (OR = 2.83; CI = 1.17-6.85) and with adenocarcinoma (OR = 3.05; CI = 1.49-6.23) were analyzed. Combinations of polymorphisms in genes involved in the same repair pathway (XPA + XPD or XRCC1 + APE1) affected lung cancer risk only in patients with SCC. These results indicate that lung cancer risk is only moderately increased by single DNA repair gene variants investigated but it is considerably enhanced by specific combinations of variant alleles. Analyses of additional DNA repair gene interactions in larger population-based studies are warranted for identification of high-risk subjects.
据报道,DNA修复基因中的几种多态性与肺癌风险相关,包括XPA(-4G/A)、XPD(Lys751Gln和Asp312Asn)、XRCC1(Arg399Gln)、APE1(Asp148Glu)和XRCC3(Thr241Met)。由于关于这些变体联合效应的信息较少,因此在一项病例对照研究中对多态性进行了分析,该研究包括463例肺癌病例[其中204例腺癌和212例鳞状细胞癌(SCC)]以及460例无肿瘤的医院对照。计算了单独变体及其组合经年龄、性别、吸烟和职业暴露调整后的优势比(OR)。对于携带APE1 Glu变体的纯合个体,发现有保护作用(OR = 0.77,CI = 0.51 - 1.16)。XPA(-4A)变体(OR = 1.53,CI = 0.94 - 2.5)、XPD 751Gln(OR = 1.39,CI = 0.90 - 2.14)或XRCC3 241Met(OR = 1.29,CI = 0.85 - 1.98)的纯合个体总体上患肺癌的风险略高。在腺癌病例亚组中,XPA(-4A)纯合个体(OR = 1.62,CI = 0.91 - 2.88)和XRCC3 241Met纯合个体(OR = 1.65;CI = 0.99 - 2.75)的调整后OR升高。在分析变体等位基因的联合效应时,鉴定出54例患者和对照为两个或三个潜在风险等位基因的纯合子[即核苷酸切除修复中的变体XPA(-4A)和XPD 751Gln,以及同源重组中的XRCC3 - 241Met]。当分析所有患者(OR = 2.37;CI = 1.26 - 4.48)、SCC患者(OR = 2.83;CI = 1.17 - 6.85)和腺癌患者(OR = 3.05;CI = 1.49 - 6.23)时,OR显著升高。参与相同修复途径的基因中的多态性组合(XPA + XPD或XRCC1 + APE1)仅在SCC患者中影响肺癌风险。这些结果表明,所研究的单个DNA修复基因变体仅适度增加肺癌风险,但特定的变体等位基因组合会显著增强风险。有必要在更大规模的基于人群的研究中分析其他DNA修复基因相互作用,以识别高危个体。